EVALI stands for e-cigarette or vaping product use-associated lung injury and emerged as a distinct public health concern in 2019. This overview explains what EVALI is, how it presents clinically, which products and substances have been linked to outbreaks, and how diagnostic criteria, surveillance, and regulatory actions aim to reduce harm. It draws on epidemiologic patterns, clinical guidance, and public health reports to separate confirmed findings from hypotheses. You will find specifics on illness trends, risk factors, treatments, and long-term implications for patients, clinicians, and regulators.
Definition and Clinical Recognition
EVALI is a syndrome of acute lung injury temporally associated with e-cigarette or vaping product use. Health authorities define it through a standardized case definition that requires compatible respiratory symptoms plus evidence of acute lung injury on imaging, in the absence of an alternative plausible cause. Providers rely on clinical judgment, exposure history, and exclusion of infections or other lung diseases. Recognizing EVALI early is important because it can deteriorate rapidly, sometimes requiring intensive care, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) in severe cases.
Epidemiology and Notable Outbreak Patterns
During 2019 and 2020, EVALI cases were reported across multiple countries, with the United States experiencing a large public health response. Cases were often clustered among adolescents and young adults, many of whom reported using vaping products containing tetrahydrocannabinol (THC), nicotine, or both. The timing, geographic distribution, and patient profiles suggested that a common exposure, likely tied to illicit THC-containing vaping products, drove much of the outbreak. Public health agencies issued warnings, conducted product recalls, and updated clinical guidance to curb further injuries.
Reported Case Numbers and Trends
| Metric | Reported Estimate or Range | Context |
|---|---|---|
| Peak weekly cases (US, 2019) | Over 200 | High during summer and fall 2019 |
| Total US cases (by Dec 2019) | Roughly 2,800 | Reported to CDC surveillance systems |
| US deaths as of Jan 2020 | 68 | Deaths associated with EVALI in official reports |
| Reported cases by late 2020 onward | Marked decline | Coincided with regulatory actions and product removals |
Products, Substances, and Identified Risk Factors
Investigations pointed primarily to illicit THC vaping products obtained from informal sources as a major driver of the EVALI outbreak. Vitamin E acetate, a thickening agent used in some illicit THC formulations, was strongly associated with cases in the US and was found in pulmonary samples of affected patients. Nicotine-containing products from commercial, regulated markets were less frequently implicated, though contamination or co-use could not be ruled out in every instance. Patients with EVALI often reported using multiple vaping products, complicating attribution and underscoring the importance of substance and source tracking.
Substances and Product Types Linked to Higher Risk
- Illicit THC vape cartridges and liquids, often obtained off-market or from informal dealers
- Vitamin E acetate detected in many THC-containing samples linked to EVALI
- Products containing THC, particularly when used with modified devices or non-standard practices
- Combination use of nicotine and THC vaping products reported by many patients
Diagnosis, Treatment, and Clinical Management
Clinicians diagnose EVALI by combining respiratory symptoms, chest imaging findings, and a history of vaping recent exposure, while excluding infections and other etiologies. Management focuses on supportive care, often in an hospital setting, with supplemental oxygen and, in critical cases, mechanical ventilation or ECMO. Corticosteroids have been used in some cases, but no single treatment has been universally adopted. Close monitoring for complications such as persistent respiratory impairment and secondary infection is part of post-acute follow-up. Most patients show improvement with time, but some experience lasting decrements in lung function.
Public Health Response and Regulatory Actions
As EVALI cases rose, health agencies issued alerts, updated clinical guidance, and worked with regulators to remove harmful products from markets. Many jurisdictions moved to restrict sales of flavored vaping products, tighten age verification, and monitor illicit THC markets. Manufacturers and retailers faced increased scrutiny, and product testing requirements were strengthened in several regions. These actions contributed to a decline in reported cases, though the long-term effectiveness of specific policies remains under study. Communication strategies aimed at youth, healthcare providers, and consumers have continued to emphasize risks associated with unregulated vaping products.
Long-Term Implications and Ongoing Considerations
Even after acute illness resolves, some individuals report persistent cough, dyspnea, or reduced exercise tolerance, highlighting the need for longitudinal follow-up. The outbreak accelerated research into vaping-related lung injury mechanisms, including aerosol chemistry, host susceptibility, and product characteristics. Clinicians are advised to maintain a high index of suspicion for vaping-associated lung injury, especially in younger patients with compatible exposure histories. Public health surveillance continues to track trends in both legal and illicit markets to inform future prevention strategies.
Key Takeaways
- EVALI is a serious, vaping-associated lung injury first identified broadly in 2019
- Illicit THC vaping products, sometimes containing vitamin E acetate, are strongly linked to the outbreak
- Clinical diagnosis uses imaging and exposure history while ruling out other causes
- Management is primarily supportive, with variable recovery timelines and some long-term sequelae
- Regulatory actions, product removals, and public communication contributed to case declines but surveillance remains active
Frequently Asked Questions
What is EVALI?
EVALI stands for e-cigarette or vaping product use-associated lung injury. It is an acute lung condition linked to vaping, characterized by respiratory symptoms and lung injury on imaging.
Which products are most associated with EVALI?
Illicit THC vaping products obtained outside regulated markets have been most strongly associated, particularly those containing vitamin E acetate.
How is EVALI treated?
Treatment is primarily supportive, often involving oxygen, hospitalization, and in severe cases, mechanical ventilation or ECMO. There is no single proven therapy.
Can EVALI cause long-term damage?
Some individuals experience persistent respiratory symptoms or reduced lung function after recovery, though many improve over time.
Are regulated nicotine products safe from EVALI risk?
Commercial nicotine-only products from regulated markets appear less commonly linked, but the possibility of contamination or co-use with illicit products means caution is advised.